Search | Clinical Trials Finder

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: simvastatin, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 40 Years to 80 Years
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 35
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more

Conditions: Chronic Airway Disease, Interstitial Lung Disease, Lung Cancer
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 2,122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions: Not listed
Lead sponsor: Epic Research & Diagnostics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COPD, OSA
Interventions: Exercise; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Salem, Virginia

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 42
States / cities: Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tetrahydrobiopterin (BH4), Antioxidant Cocktail; Drug · Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Asthma
Interventions: TNFR:Fc; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate (FF)/GW642444 Inhalation Powder, placebo; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 8
States / cities: DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more

Conditions: COPD, Chronic Musculoskeletal Pain
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Benralizumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Scottsboro, Alabama • Gilbert, Arizona • Denver, Colorado + 13 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 40 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 76
States / cities: Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Chronic Obstructive Pulmonary Disease, HIV, Emphysema
Interventions: blood draw, questionnaires, Lung function testing, Six-Minute walk test, Quantitative CT scans, Nasal secretion and cell collection, Echocardiogram; Procedure · Radiation
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Asthma
Interventions: FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI); Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 2,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 99
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more

Conditions: CVA (Cerebrovascular Accident)
Interventions: myomo e100 neurorobotic elbow brace; Device
Lead sponsor: Myomo; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disorder
Interventions: BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg, BD MDI 320 μg, Symbicort® TBH 400/12 μg BID; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 83
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 70 more

Conditions: Emphysema
Interventions: Spiration Valve System, Medical Management; Device · Other
Lead sponsor: Olympus Corporation of the Americas; Industry
Eligibility: 40 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 32
States / cities: Fort Smith, Arkansas • Riverside, California • San Diego, California + 28 more

Conditions: Copd, Smoking, Tobacco Use
Interventions: Bronchoscopy with Bronchoalveolar Lavage (BAL); Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2030
U.S. locations: 3
States / cities: San Francisco, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 40 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 4
States / cities: San Antonio, Texas • Seattle, Washington

Conditions: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Roflumilast; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 32
States / cities: Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in California, California + 29 more

Conditions: Constrictive Bronchiolitis, Iraq-Afganistan War Lung Injury Syndrome
Interventions: Perfluorinated Gas/Oxygen Mixture; Diagnostic Test
Lead sponsor: Hal C Charles; Other
Eligibility: 18 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 59
States / cities: *See Various Dept.'s*, Arizona • Chandler, Arizona • Fresno, California + 48 more

Conditions: Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions: Advanced multi-component meditation practice; Behavioral
Lead sponsor: Tobias Moeller-Bertram; Industry
Eligibility: 21 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Palm Desert, California

Search by objective public record fields.

Simvastatin Therapy for Moderate and Severe COPD

WTC Chest CT Imaging Archive

Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology

Prognostic Indicators as Provided by the EPIC ClearView

The Effect of Interval Exercise on Functional Outcomes in Veterans With COPD and OSA

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)

Study of TNFR:Fc (Enbrel) in the Treatment of Asthma

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

BRAIN, Symptoms, and Physical Activity in COPD

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Wearable Robotic Functional Assistance for Stroke Rehabilitation

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function

Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

Iraq- Afghanistan War Lung Injury Using 19F MRI (DIAL1001006)

NVA237 BID Versus Placebo Twelve-week Efficacy Study

Quest to Analyze One Thousand Humans Meditating